Showing 3,201 - 3,220 results of 6,235 for search 'Wang Laboratories', query time: 0.07s Refine Results
  1. 3201
  2. 3202
  3. 3203
  4. 3204
  5. 3205
  6. 3206
  7. 3207
  8. 3208
  9. 3209
  10. 3210
  11. 3211

    Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents by Zhang Y, Xia H, Fan L, Jiang L, Yang B, Wang F

    Published 2025-01-01
    “…Yaping Zhang,1,2,* Huan Xia,3,* Luchang Fan,1 Lu Jiang,4 Bin Yang,2 Fengmei Wang4,5 1The Third Central Clinical College of Tianjin Medical University, Tianjin Medical University, Tianjin, 300170, People’s Republic of China; 2Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Nankai University Affiliated Third Central Hospital, Tianjin, 300072, People’s Republic of China; 3Department of Infectious Diseases, Tianjin Second People’s Hospital, Tianjin, 300192, People’s Republic of China; 4Department of Hepatology and Gastroenterology, Tianjin First Central Hospital, Tianjin, 300192, People’s Republic of China; 5Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Central Hospitial, Tianjin, 300192, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fengmei Wang; Bin Yang, Email wangfengmeitj@126.com; bioyang@126.comPurpose: The research intended to present prospective data on the long-term prognosis of individuals with hepatitis C virus (HCV) infection who received direct-acting antiviral agent (DAA) treatment.Patients and Methods: Patients who received DAA treatment at Tianjin Third Central Hospital and Tianjin Second People’s Hospital were prospectively enrolled and subsequently underwent a longitudinal follow-up. …”
    Get full text
    Article
  12. 3212

    Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models by Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X, Song S

    Published 2025-01-01
    “…Yi Liu,1– 4,* Xiao Wang,1– 3,5,* Ni Zhang,1– 4,* Simin He,1– 4 Jianping Zhang,1– 4 Xiaoping Xu,1– 4 Shaoli Song1– 4 1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China; 3Center for Biomedical Imaging, Fudan University, Shanghai, 200032, People’s Republic of China; 4Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, People’s Republic of China; 5State Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory & Center for Molecular Imaging and Translational Medicine, School of Public Health, Shenzhen Research Institute of Xiamen University, Xiamen University, Xiamen, 361102, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shaoli Song; Xiaoping Xu, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China, Email shaoli-song@163.com; xxp0012@ustc.eduPurpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits. …”
    Get full text
    Article
  13. 3213
  14. 3214
  15. 3215
  16. 3216
  17. 3217
  18. 3218
  19. 3219
  20. 3220